We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

The business has a 50 day moving average of $49.72 and a 200 day moving average of $52. ... The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology ...

The final appraisal document for Dupixent (dupilumab ... ILD is a diverse collection of more than 200 lung disorders, and around 13% to 40% of patients go on to develop progressive disease.

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

The company has a 50-day simple moving average of $48.90 and a 200-day simple moving average ... The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

And that's a mix of roughly $300 million rheum, $200 million derm ... So in several large markets, we actually are ahead of Dupixent. And some of that has to do with the way that the label ...